


Sjögren's Quarterly

The Professionals' Resource on Sjögren's

Vol. 16, Issue 3 - Summer 2021



New ICD-10 Codes for Sjögren's Go into Effect Fall 2021!

he Sjögren's Foundation is excited to share that the new ICD-10 codes for Sjögren's will take effect in the U.S. beginning October 1, 2021. This initiative, which was done in partnership with the American College of Rheumatology (ACR), has culminated in a successful effort to revise the existing ICD-10 code for Sjögren's. These changes are expected to be folded into the ICD-11 Code for international use.

This initiative, which began in 2017, was undertaken with the recognition that the existing ICD-10 (International Statistical Classification of Diseases and Related Health Problems, 10th revision) code for Sjögren's (M35.0, Sicca syndrome [Sjogren]) does not represent the disease and contributes to misinformation and confusion. Changes to the code, which are mentioned in detail later in this article, will benefit providers, investigators, researchers, insurers, and, of course, patients, and address key complications of Sjögren's that were not included in the current code.

Rationale for this Initiative

The current code uses "Sicca syndrome" and "Sjögren's" synonymously. While at one point this may have been a prevailing thought, we know that using these terms interchangeably is inaccurate for a variety of reasons.

Sicca is a symptom and not a disease, while Sjögren's is a distinct systemic autoimmune, rheumatic disease that can affect multiple organs and body systems. Dryness certainly occurs in Sjögren's, but dryness alone does not represent the disease and the many other symptoms involved. Furthermore, sicca includes many non-Sjögren's patients who may have dryness symptoms for numerous reasons, including radiation for head and neck cancers, graft-versus-host disease and as a side effect of certain medications.

Further justification can be found when looking at classification criteria. Sjögren's classification criteria has never used either "sicca" nor "sicca syndrome," and no criteria exist for "sicca syndrome." Using the 2002 American European Consensus Criteria (AECC) and the 2016 ACR-EULAR criteria as examples, we can see that these criteria rely primarily on serology and biopsy, and in no way indicate that Sjögren's be defined by sicca.

The current ICD-10 code creates confusion, contributes to misinformation and is potentially detrimental to patients, whose diagnosis carries an incorrect label, which can influence subsequent difficulty with insurance reimbursement, clinicians, who may be unsure of how to best code the disease, study investigators and researchers, who may have trouble accurately identifying Sjögren's patients for clinical trials and data acquisition, and insurers, who grapple with inaccuracy, which can influence reimbursement to both patients and providers.

Continued on page 2 V



5 Sjögren's Foundation New Grants for FY22

8 Clinical News

13 Scientific News

15 Sjögren's Foundation In Action





Medical and Scientific Advisors

Chair

Alan Baer, MD

Members

Esen Akpek, MD Penny A. Asbell, MD, FACS, MBA Herbert S. Baraf, MD, MACR Richard Brasington, MD, FACR Michael Brennan, DDS, MHS Steven E. Carsons, MD* Nancy L. Carteron, MD, FACR Troy Daniels, DDS, MS* Denise L. Faustman, MD, PhD H. Kenneth Fisher, MD, FACP, FCCP Gary Foulks, MD, FACS S. Lance Forstot, MD Philip C. Fox, DDS* Robert I. Fox, MD, PhD, FACP* Theresa Lawrence Ford, MD, FACR Tara Mardigan, MS, MPH, RD Austin Mircheff, PhD John Daniel Nelson, MD, FACS Kelly Nichols, OD Athena Papas, DMD, PhD Ann Parke, MD Andres Pinto, DMD Nelson Rhodus, DMD, MPH Vidya Sankar, DMD, MHS Daniel Small, MD, FACP Neil Stahl, MD Frederick B. Vivino, MD, FACR Jeffrey Wilson, MD, FACR

Associate Members

Simon J. Bowman, PhD, FCRP Janine A. Clayton, MD Arthur Grayzel, MD, FACR* Roland Jonsson, DMD, PhD Stuart S. Kassan, MD, FACP* Robert Lebovics, MD Michael Lemp, MD* Xavier Mariette, MD Haralampos M. Moutsopoulos, MD* Manuel Ramos-Casals, MD, PhD James J. Sciubba, DMD, PhD* Athanasios G. Tzioufas, MD Ira J. Udell, MD* Claudio Vitali, MD Daniel J. Wallace, MD Pierre Youinou, MD, Dsc *Counselor

Editor

Matt Makara, MPH

Executive & Founding Editor Katherine M. Hammitt, MA

Medical & Scientific Editor Nancy Carteron, MD, FACR

Co-Medical & Scientific Editors

Vidya Sankar, DMD S. Lance Forstot, MD

Editors and Reviewers Esen K. Akpek, MD Herbert S.B. Baraf, MD, FACP, MACR Donald E. Thomas, MD, FACR

> Sjögren's Foundation CEO Janet E. Church

e-mail: sq@Sjögrens.org www.Sjögrens.org

"ICD-10 Changes" continued from page 1 ▼

What's Changing?

The following changes are set to take effect in October, 2021:

Tabular Modifications

M35 Other systemic involvement of connective tissue


Revise	M35.0	Sicca syndrome [Sjogren] Sjogren syndrome
	Add	Sicca syndrome
	Add	Excludes1: Dry mouth, unspecified (R68.2)
Revise	M35.00	Sicca Sjogren syndrome, unspecified
Revise	M35.01	Sicca Sjogren syndrome with keratoconjunctivitis
Revise	M35.02	Sicea Sjogren syndrome with lung involvement
Revise	M35.03	Sicca Sjogren syndrome with myopathy
Revise	M35.04	Sicca Sjogren syndrome with tubulo-interstitial
		nephropathy
New code	M35.05	Sjogren syndrome with inflammatory arthritis
New code	M35.06	Sjogren syndrome with peripheral nervous system
		involvement
New code	M35.07	Sjogren syndrome with central nervous system
		involvement
New code	M35.08	Sjogren syndrome with gastrointestinal involvement
New code	M35.0A	Sjogren syndrome with glomerular disease
New code	M35.0B	Sjogren syndrome with vasculitis
New code	M35.0C	Sjogren syndrome with dental involvement
Revise	M35.09	Sicca Sjogren syndrome with other organ involvement

It is important to note that patients with symptoms of dryness who cannot definitively be linked to Sjögren's, can still be designated under the Symptoms section of the ICD Code.

The Process

From the onset, those involved knew this would be no small task. However, the importance of this initiative helped motivate a team of multi-disciplinary experts, represented by a non-profit, professional society, academia, industry, rheumatology, pediatric rheumatology, primary care, neurology, gastroenterology, pulmonology, nephrology, oncology, ophthalmology and oral medicine, to convene and collaborate on the best course forward.

After a series of meetings and discussions, a proposal was submitted to the ICD-10 Coordination and Maintenance Committee (C&M), a federal interdepartmental committee comprised of representatives from the Centers for



Sjögren's Quarterly Newsletter is published by the Sjögren's Foundation Inc., 10701 Parkridge Boulevard, Suite 170, Reston, VA 20191. Copyright ©2021 Sjögren's Foundation Inc. ISSN 0899-637.

DISCLAIMER: The Sjögren's Foundation Inc. in no way endorses any of the medications, treatments, or products mentioned in advertisements or articles. This newsletter is for informational purposes only.

4

"ICD-10 Changes" continued from page 2 ▼

Medicare and Medicaid Services (CMS) and the Centers for Disease Control and Prevention's (CDC) National Center for Health Statistics (NCHS), with suggestions for modifications to the code for Sjögren's.

Excitingly, the proposal was accepted for presentation at the Fall C&M meeting taking place near Baltimore, MD, in September 2018. Here, Dr. Alan Baer represented the Sjögren's Foundation, ACR and the multi-disciplinary team who informed the proposal by expertly explaining the rationale for why changes to the Sjögren's code are needed. Dr Baer's presentation was followed by a presentation by a CDC representative detailing the specific tabular changes that were being requested.

A period for public comment took place in the subsequent months after the meeting, during which few questions were raised. However, as the group learned, because questions had been raised, the proposed changes would need to be revised to address the questions and the proposal presented at the Spring C&M meeting in March, 2019.

This time, only a CDC representative was needed for the presentation of the proposal, and Kathy Hammitt, Vice President of Medical and Scientific Affairs, was on hand to provide perspective on the few questions that were raised. An additional public comment period was then held but resulted in no major issues being put forth.

A Team Effort

This effort was no-doubt strengthened by the multidisciplinary team who provided their time and expertise in guiding this project. The Sjögren's Foundation is sincerely grateful to the advisory team, who provided integral help throughout the entire process, and would like to recognize and thank the following individuals:

Alan N. Baer, MD

Director, Jerome Greene Sjögren's Syndrome Clinic & Professor of Medicine, Johns Hopkins University School of Medicine (Rheumatology)

Theresa Lawrence Ford, MD

CEO & Medical Director, North Georgia Rheumatology Group (Rheumatology)

Frederick Vivino, MD

Director, Sjögren's Syndrome Center, Perelman School of Medicine at the University of Pennsylvania (Rheumatology)

Nancy Carteron, MD

University of California San Francisco, University of California Berkeley, School of Optometry, Sjogren's Clinic (Rheumatology)

Scott Lieberman, MD

University of Iowa (Pediatric Rheumatology)

Judith Furlong, MD

ProMedica Physicians Family Medicine (Primary Care)

Julius Birnbaum, MD

Co-director, Jerome Greene Sjögren's Syndrome Clinic, Johns Hopkins University School of Medicine (Neurology & Rheumatology)

Augustine Lee, MD

Mayo Clinic, Jacksonville, FL (Pulmonology)

Marie Hogan, MD

Mayo Clinic, Rochester, MN (Nephrology)

Lance Forstot, MD

Corneal Consultants of Colorado (Ophthalmology)

Vidya Sankar, DMD

Brigham and Women's Hospital (Oral Medicine)

Richard Ambinder, MD, PhD

Johns Hopkins University School of Medicine (Oncology)

Katerina Shetler, MD

Palo Alto Medical Foundation (Gastroenterology)

Jo Annah Jensen

Novartis (Industry)

Steven Taylor

Sjögren's Foundation

Kathy Hammitt

Sjögren's Foundation

Antanya Chung

American College of Rheumatology

A special thank you to Alan Baer, MD, for presenting, inperson, at CMS headquarters during the ICD-10 Coordination and Maintenance Committee meeting in September 2018. Dr. Baer's presence and presentation very eloquently made a case for the proposed changes and helped set us apart by being one of the only presenters outside of CMS and CDC staff during the event.

The Sjögren's Foundation would also like to recognize Antanya Chung and the American College of Rheumatology for their support and collaboration on this important initiative.

Editor's Note

The original version of this article appeared in the Fall 2019 issue of Sjögren's Quarterly. After publication, unforeseen delays in implementation were experienced, and this article is being reprinted as a reminder to our subscribers of the important changes that will be taking place. The affiliations for team members listed on page 4 were accurate at the time of the original publication, but may have since changed.